ASX - By Stock
|
BIT |
Re:
Take Over Offer is over the cup for sure!
|
|
Selvan
|
112 |
31K |
10 |
12/04/23 |
12/04/23 |
ASX - By Stock
|
112
|
31K
|
10
|
|
ASX - By Stock
|
BIT |
Re:
Ann: BIT225 Effectiveness Against COVID-19 in Animals
|
|
Selvan
|
167 |
67K |
4 |
17/03/22 |
17/03/22 |
ASX - By Stock
|
167
|
67K
|
4
|
|
ASX - By Stock
|
BIT |
Re:
Ann: BIT225 Effectiveness Against COVID-19 in Animals
|
|
Selvan
|
167 |
67K |
5 |
17/03/22 |
17/03/22 |
ASX - By Stock
|
167
|
67K
|
5
|
|
ASX - By Stock
|
BIT |
Re:
Ann: BIT225 Effectiveness Against COVID-19 in Animals
|
|
Selvan
|
167 |
67K |
3 |
17/03/22 |
17/03/22 |
ASX - By Stock
|
167
|
67K
|
3
|
|
ASX - By Stock
|
BIT |
Re:
The Divine Miss M
|
|
Selvan
|
21 |
18K |
2 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
21
|
18K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive results reaffirm plans to advance ATL1102 to P2b
|
|
Selvan
|
87 |
47K |
1 |
17/12/19 |
17/12/19 |
ASX - By Stock
|
87
|
47K
|
1
|
|
ASX - By Stock
|
EPN |
Re:
Ann: First Medicinal Cannabis Processed at Southport Facility
|
|
Selvan
|
81 |
37K |
5 |
04/12/19 |
04/12/19 |
ASX - By Stock
|
81
|
37K
|
5
|
|
ASX - By Stock
|
EPN |
Re:
Ann: First Medicinal Cannabis Processed at Southport Facility
|
|
Selvan
|
81 |
37K |
5 |
04/12/19 |
04/12/19 |
ASX - By Stock
|
81
|
37K
|
5
|
|
ASX - By Stock
|
EPN |
Re:
Ann: First Medicinal Cannabis Processed at Southport Facility
|
|
Selvan
|
81 |
37K |
7 |
04/12/19 |
04/12/19 |
ASX - By Stock
|
81
|
37K
|
7
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Presentation of HIV Data to CROI and New Patents
|
|
Selvan
|
59 |
40K |
2 |
03/12/19 |
03/12/19 |
ASX - By Stock
|
59
|
40K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Presentation of HIV Data to CROI and New Patents
|
|
Selvan
|
59 |
40K |
5 |
03/12/19 |
03/12/19 |
ASX - By Stock
|
59
|
40K
|
5
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Trading Halt
|
|
Selvan
|
58 |
44K |
4 |
02/12/19 |
02/12/19 |
ASX - By Stock
|
58
|
44K
|
4
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Trading Halt
|
|
Selvan
|
58 |
44K |
8 |
02/12/19 |
02/12/19 |
ASX - By Stock
|
58
|
44K
|
8
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Trading Halt
|
|
Selvan
|
58 |
44K |
7 |
02/12/19 |
02/12/19 |
ASX - By Stock
|
58
|
44K
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
Selvan
|
5.9K |
2.3M |
2 |
19/11/19 |
19/11/19 |
Charts
|
5.9K
|
2.3M
|
2
|
|
ASX - By Stock
|
EPN |
Re:
Ann: THC Global Shareholder Update
|
|
Selvan
|
15 |
7.7K |
9 |
19/11/19 |
19/11/19 |
ASX - By Stock
|
15
|
7.7K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Selvan
|
29 |
17K |
3 |
15/11/19 |
15/11/19 |
ASX - By Stock
|
29
|
17K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Selvan
|
29 |
17K |
2 |
14/11/19 |
14/11/19 |
ASX - By Stock
|
29
|
17K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Secures $5.1 Million Underwriting Agreement
|
|
Selvan
|
73 |
48K |
2 |
12/11/19 |
12/11/19 |
ASX - By Stock
|
73
|
48K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Secures $5.1 Million Underwriting Agreement
|
|
Selvan
|
73 |
48K |
5 |
12/11/19 |
12/11/19 |
ASX - By Stock
|
73
|
48K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Combined Therapies for DMD
|
|
Selvan
|
189 |
92K |
5 |
12/11/19 |
12/11/19 |
ASX - By Stock
|
189
|
92K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Combined Therapies for DMD
|
|
Selvan
|
189 |
92K |
6 |
12/11/19 |
12/11/19 |
ASX - By Stock
|
189
|
92K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
Selvan
|
39 |
18K |
3 |
11/11/19 |
11/11/19 |
ASX - By Stock
|
39
|
18K
|
3
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Manufacturing Permit Received for Southport Facility
|
|
Selvan
|
71 |
34K |
3 |
11/11/19 |
11/11/19 |
ASX - By Stock
|
71
|
34K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
Selvan
|
39 |
18K |
17 |
11/11/19 |
11/11/19 |
ASX - By Stock
|
39
|
18K
|
17
|
|
Charts
|
PER |
Re:
Chart
|
|
Selvan
|
5.9K |
2.3M |
3 |
08/11/19 |
08/11/19 |
Charts
|
5.9K
|
2.3M
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
Selvan
|
5.9K |
2.3M |
1 |
08/11/19 |
08/11/19 |
Charts
|
5.9K
|
2.3M
|
1
|
|
Charts
|
PER |
Re:
Chart
|
|
Selvan
|
5.9K |
2.3M |
4 |
08/11/19 |
08/11/19 |
Charts
|
5.9K
|
2.3M
|
4
|
|
ASX - By Stock
|
PER |
Re:
Sarepta eyes multiple sclerosis gene therapy
|
|
Selvan
|
40 |
18K |
6 |
05/11/19 |
05/11/19 |
ASX - By Stock
|
40
|
18K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Sarepta eyes multiple sclerosis gene therapy
|
|
Selvan
|
40 |
18K |
3 |
05/11/19 |
05/11/19 |
ASX - By Stock
|
40
|
18K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Sarepta eyes multiple sclerosis gene therapy
|
|
Selvan
|
40 |
18K |
6 |
05/11/19 |
05/11/19 |
ASX - By Stock
|
40
|
18K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Sarepta eyes multiple sclerosis gene therapy
|
|
Selvan
|
40 |
18K |
4 |
05/11/19 |
05/11/19 |
ASX - By Stock
|
40
|
18K
|
4
|
|
ASX - By Stock
|
EPN |
Re:
Ann: THC Global Corporate Presentation - Sept 2019
|
|
Selvan
|
119 |
51K |
3 |
05/11/19 |
05/11/19 |
ASX - By Stock
|
119
|
51K
|
3
|
|
ASX - By Stock
|
BIT |
Re:
$10 Billion Deal
|
|
Selvan
|
13K |
6.3M |
3 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
13K
|
6.3M
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: Techknow Conference Presentation
|
|
Selvan
|
89 |
45K |
2 |
23/10/19 |
23/10/19 |
ASX - By Stock
|
89
|
45K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Techknow Conference Presentation
|
|
Selvan
|
89 |
45K |
11 |
23/10/19 |
23/10/19 |
ASX - By Stock
|
89
|
45K
|
11
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Two Facilities Receive S4 and S8 Narcotics Licences
|
|
Selvan
|
41 |
14K |
10 |
17/10/19 |
17/10/19 |
ASX - By Stock
|
41
|
14K
|
10
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Two Facilities Receive S4 and S8 Narcotics Licences
|
|
Selvan
|
41 |
14K |
6 |
17/10/19 |
17/10/19 |
ASX - By Stock
|
41
|
14K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to present at Neuromuscular Drug Development Summit USA
|
|
Selvan
|
44 |
21K |
10 |
17/10/19 |
17/10/19 |
ASX - By Stock
|
44
|
21K
|
10
|
|
ASX - By Stock
|
EPN |
Re:
Ann: Two Facilities Receive S4 and S8 Narcotics Licences
|
|
Selvan
|
41 |
14K |
7 |
17/10/19 |
17/10/19 |
ASX - By Stock
|
41
|
14K
|
7
|
|
ASX - By Stock
|
EPN |
Re:
THCO Options (THCO)
|
|
Selvan
|
73 |
46K |
0 |
16/10/19 |
16/10/19 |
ASX - By Stock
|
73
|
46K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Selvan
|
130 |
64K |
9 |
14/10/19 |
14/10/19 |
ASX - By Stock
|
130
|
64K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Selvan
|
130 |
64K |
4 |
09/10/19 |
09/10/19 |
ASX - By Stock
|
130
|
64K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
Selvan
|
5.9K |
2.3M |
2 |
09/10/19 |
09/10/19 |
Charts
|
5.9K
|
2.3M
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
Selvan
|
5.9K |
2.3M |
5 |
08/10/19 |
08/10/19 |
Charts
|
5.9K
|
2.3M
|
5
|
|
ASX - By Stock
|
PER |
Re:
Some Antisense Deal Numbers
|
|
Selvan
|
12 |
6.3K |
9 |
08/10/19 |
08/10/19 |
ASX - By Stock
|
12
|
6.3K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive preliminary results from ATL1102 DMD Phase II trial
|
|
Selvan
|
595 |
347K |
9 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
595
|
347K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive preliminary results from ATL1102 DMD Phase II trial
|
|
Selvan
|
595 |
347K |
7 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
595
|
347K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive preliminary results from ATL1102 DMD Phase II trial
|
|
Selvan
|
595 |
347K |
2 |
04/10/19 |
04/10/19 |
ASX - By Stock
|
595
|
347K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Chance of extending ANPOB options?
|
|
Selvan
|
31 |
12K |
1 |
04/10/19 |
04/10/19 |
ASX - By Stock
|
31
|
12K
|
1
|
|